Stocktoria
Akebia Therapeutics, Inc. AKBA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-20
Akebia Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 9.9% | -31.5% | -23.8% | -27.6% | -124.2% |
| Net margin | -2.3% | -43.3% | -26.7% | -32.2% | -132.0% |
| FCF margin | 28.7% | -25.4% | -12.0% | -25.1% | -118.5% |
| Return on assets | -1.4% | -31.5% | -21.5% | -26.5% | -53.7% |
| Return on equity | -16.4% | 141.1% | 169.8% | -1801.6% | -381.1% |
| Debt / equity | 1.48× | -0.79× | -1.13× | 12.63× | 1.32× |
| Current ratio | 1.55 | 1.41 | 1.18 | 1.43 | 1.06 |
| Revenue growth | 47.5% | -17.7% | -33.5% | 36.9% | -27.7% |
Source: SEC EDGAR filings · CIK 0001517022 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.